| Brand Name | Ibrance |
| Packaging Type | Blister |
| Molecule | Palbociclib |
| Generic Name | Palbociclib 125mg |
| Manufactured By | Pfizer Inc. |
| Quantity | 21 tablets |
| Form | Tablet |
| Country of Origin | India |
| Categories | Oncology |
Palbociclib 125mg is used to treat hormone receptor-positive (HR+), and HER2-negative advanced or metastatic breast cancer.
The duration of treatment with palbociclib varies based on how well the patient responds to it and any side effects experienced. Many patients continue treatment as long as the cancer responds and the side effects are manageable.
Ibrance Palbociclib 125mg is a targeted therapy drug rather than traditional chemotherapy. It is a CDK4/6 inhibitor that specifically targets proteins involved in cancer cell growth, slowing the progression of HR+ and HER2-negative breast cancer.
While on palbociclib, it is recommended to avoid grapefruit and grapefruit juice, as they can interfere with how the drug is processed in the body and may increase side effects.
Yes, a prescription is required for Ibrance. It is a specialized cancer medication that must be prescribed by a healthcare provider who will determine if it’s suitable for the patient's condition.
